Table S3. Comparison of TAVR with SAPIEN 3 OR EVOLUT R/PRO versus SAVR at 1-year.
| Outcome | Studies | Event rate | Odds ratio (95% CI) | I2 | P value | |
|---|---|---|---|---|---|---|
| TAVR | SAVR | |||||
| All-cause mortality | 2 | 22/1,221 (1.8%) | 31/1,132 (2.7%) | 0.65 (0.37–1.17) | 5% | 0.15 |
| Cardiac mortality | 2 | 16/1,221 (1.3%) | 27/1,132 (2.4%) | 0.55 (0.29–1.02) | 0% | 0.06 |
| Stroke | 2 | 36/1,221 (2.9%) | 43/1,132 (3.8%) | 0.67 (0.28–1.62) | 63% | 0.37 |
| Atrial fibrillation | 2 | 100/1,221 (8.1%) | 410/1,132 (36.2%) | 0.15 (0.11–0.21) | 36% | <0.0001 |
| Permanent pacemaker | 2 | 177/1,221 (14.5%) | 69/1,132 (6.09%) | 2.23 (0.94–5.31) | 86% | 0.007 |
| All-cause rehospitalization | 2 | 59/1,221 (4.8%) | 93/1,132 (8.2%) | 0.56 (0.40–0.79) | 0% | 0.001 |
| Mod-severe paravalvular regurgitation | 2 | 18/871 (2.06%) | 4/708 (0.6%) | 3.00 (0.60–15.01) | 48% | 0.18 |
CI, confidence interval; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.